碧桂園(02007.HK)斥4.15億人幣入股惠達衛浴(603385.SH)
內地浴室設備生產商惠達衛浴(603385.SH)公布,與碧桂園(02007.HK)旗下深圳市碧桂園創新投資簽署股份認購協議,碧桂園將以4.15億元人民幣(下同)認購約5,060.98萬股非公開發行股份,認購價格每股8.2元,限售期18個月。
公告指,碧桂園將成為持股5%以上的戰略投資者,長期持股及委派一名董事參與惠達衛浴日常治理。雙方計劃在住宅、商場、酒店等領域就衛生潔具、陶瓷磚及裝配式整體浴室等產品進行長期供貨合作。
碧桂園(02007.HK)積極佈署進入家品行業,月初曾斥資約5億元入股內地瓷磚生產商蒙娜麗莎(002918.SZ),上月亦成為帝歐家居(002798.SZ)的戰略投資者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.